Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06211257 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

Study acronym: ePPS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Secondary endpoints revised (7)v6
  3. Primary completion date: Jun 2026 to Jul 2028v5 Show 6 more changesShow less
    • Study sites: 10 to 11
    • Study completion date: Mar 2028 to Apr 2030
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: 6 to 7
    • Study description shortened, about 6 words
    • Study title shortened, about 1 word
  4. Site details revised at 10 of 10 sitesv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2024 to May 29, 2024
    • Site details revised at 10 of 10 sites
    v3
  6. Secondary endpoints: details revised at 2 of 6 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Centre Oscar Lambret
100 trials monitored
See 2 trials at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.
Trial Details
NCT Number NCT06211257
Lead Sponsor Centre Oscar Lambret
Collaborators: Canceropôle Nord Ouest
Conditions
(from sponsor)		 Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma
Related terms Neuroaxonal Dystrophies, Sarcoma
Enrollment 377 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov